Enterprise honor of jiangsu hengrui Pharmaceutical Co., Ltd.

The company has developed 90 national new drugs with more than four categories, including 4 national first-class drugs and 2 second-class drugs 13. The company has a number of product phalanxes, 7 of which are exclusively produced in China; 13 products were rated as national new drugs, among which letrozole raw materials and preparations and ambroxol hydrochloride raw materials and preparations were included in the national torch plan. The solid preparation, freeze-dried powder injection, sterile split needle, water injection and other dosage forms of the company's products have passed the national GMP certification, and the raw materials such as ifosfamide, etoposide and mesna have passed the US FDA verification.

In April 2000, the company applied for the first patent for new compounds, and many innovative drugs were in the preclinical research stage, which marked the strategic shift from imitation to innovation. We cherish the honor we have won and will inspire us to pursue new heights in the future development process.

Recently, the "Top 20 Most Competitive Pharmaceutical Listed Companies in China and Top 20 Pharmaceutical Listed Companies with the Most Investment Value in 20 12 Years" sponsored by China Pharmaceutical Enterprise Management Association, Pharmaceutical Managers Magazine and Hejun Consulting Group were announced. With its rising brand influence, good development performance and industrial competitiveness, Hengrui Pharma ranked among the top three in the top 20 most competitive pharmaceutical listed companies in China in 20 12, and ranked among the top 20 most valuable pharmaceutical listed companies in 20 12.

It is reported that the China Listed Pharmaceutical Companies Competition is the fourth, and our company has been selected for four consecutive years. This selection activity started in March of 20 12 and lasted for four months. The financial reports of 93 China pharmaceutical companies listed in Shanghai, Shenzhen, Hongkong, Singapore, new york and Nasdaq were analyzed, with annual sales exceeding 65,438 billion yuan. Based on the company's sales revenue, profit, total market value, sales growth, profit growth, market value growth, return on net assets, asset-liability ratio and liquidity ratio in the past year, the industry dimension, management dimension and capital dimension are formed, and then the scores are weighted and summarized by questionnaire surveys of industry experts, senior securities analysts and mainstream financial media reporters. Because the evaluation system is scientific and reasonable, the selection procedure is objective and fair, and the selection results are highly oriented, it has been recognized and positively evaluated by many listed companies and industries.